Currently, APR-246 in combination with azacitidine has reached Phase III clinical trial for the treatment of TP53 mutant myelodysplastic syndromes (MDS) (NCT03745716) and Phase II for TP53 mutant myeloid neoplasms (NCT03072043, NCT03588078). Here, TP53 is linked to myeloid neoplasm.